Skip to Main Content

Fresh off a big clinical trial victory in postpartum depression, Sage Therapeutics (SAGE) announced yet more good news Thursday: Positive results from a mid-stage clinical trial for a pill to treat people with major depressive disorder. The drug appears to work quickly, though its effects diminish over time.

If Thursday’s results are confirmed in later phase 3 clinical trials, the Sage pill, known as SAGE-217, could become one of the first medicines in years with a new mechanism of action to be approved for the treatment of depression.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.